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Previous studies have suggested that urokinase
plasminogen activator is required for blister formation
in pemphigus vulgaris and pemphigus foliaceus.
Other studies, however, have shown that downregul-
ation of plasminogen activator does not inhibit
blisters induced by pemphigus immunoglobulin G.
To eliminate the possibility that small amounts of
urokinase plasminogen activator might be sufficient
for blister formation, we passively transferred pem-
phigus immunoglobulin G to urokinase plasminogen
activator knockout neonatal mice. Pemphigus folia-
ceus and pemphigus vulgaris immunoglobulin G
caused gross blisters and acantholysis in the superficial
and suprabasal epidermis, respectively, to the same
degree in knockout and control mice, demonstrating
that urokinase plasminogen activator is not absolutely
required for antibody-induced blisters. Some studies
have shown elevated tissue-type plasminogen activ-
ator in pemphigus lesions. Tissue-type plasminogen
In the two major forms of pemphigus, pemphigus vulgaris(PV) and pemphigus foliaceus (PF), autoantibodies againstdesmogleins cause loss of keratinocyte cell adhesion (alsotermed acantholysis) and blister formation (Stanley, 1989,1990). The autoantibodies from PF patients are directed
against desmoglein (Dsg) 1 and cause blisters in the superficial
living epidermis, whereas the autoantibodies in PV are directed
against Dsg3 (with or without coexisting anti-Dsg1 antibodies) and
cause blisters in the deep epidermis, just above the basal layer (i.e.,
suprabasilar acantholysis) (Buxton et al, 1993; Stanley, 1993).
Desmogleins are transmembrane glycoproteins of desmosomes,
which are cell–cell adhesion structures. Therefore, when it was
discovered that pemphigus autoantibodies bind desmogleins, it was
postulated that these antibodies might directly interfere with an
adhesion function of these desmosomal molecules (Koulu et al,
1984; Amagai et al, 1991).
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activator, however, is not necessary for blister
formation, because pemphigus foliaceus and pem-
phigus vulgaris immunoglobulin G caused blisters
to the same degree in tissue-type plasminogen
activator knockout and control mice. To rule out
that one plasminogen activator might compensate
for the other in the knockout mice, we bred
urokinase plasminogen activator, tissue-type plasmin-
ogen activator double knockouts. After passive
transfer of pemphigus foliaceus and pemphigus
vulgaris immunoglobulin G these mice blistered to
the same degree as the single knockout and control
mice, and histology indicated blisters at the expected
level of the epidermis. These data definitively demon-
strate that plasminogen activator is not necessary
for pemphigus immunoglobulin G to induce acantho-
lysis in the neonatal mouse model of pemphigus.
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There were also studies, however, that suggested that blister
formation in pemphigus is indirectly mediated by release of proteases
secondary to antibody binding (Schiltz et al, 1979; Farb et al,
1978). Furthermore, under some experimental conditions protease
inhibitors were able to inhibit acantholysis induced by PV antibodies
added to human epidermal culture and passively transferred to
neonatal mice (Farb et al, 1978; Naito et al, 1989). Most studies
that have attempted to identify the specific proteases involved in
the pathophysiology of pemphigus have implicated plasminogen
activator (PA). PF and PV immunoglobulin (Ig) G added to human
keratinocyte cell culture caused PA release, mostly of the urokinase
type (uPA) (Hashimoto et al, 1983). These same authors showed
that plasminogen (the substrate for PA) enhanced the ability of
pemphigus IgG to cause acantholysis in organ culture (Hashimoto
et al, 1983). Further studies of human skin organ culture demon-
strated that a rabbit anti-uPA antibody and PA inhibitor 2 (a potent
inhibitor of uPA) blocked acantholysis induced by PV and PF IgG
(Morioka et al, 1987; Hashimoto et al, 1989). Finally, recent studies
point to a potential mechanism of antibody-mediated PA release
from keratinocytes through the activation of protein kinase C
(Esaki et al, 1995).
In spite of these studies there are problems with implicating PA
in pemphigus blister formation. Studies showing PA release by
human keratinocytes are mostly based on cell culture, whereas
acantholysis and inhibition of acantholysis is mostly demonstrated
in organ culture. Although uPA has been implicated in cell culture,
tissue type PA (tPA) increases have been found in lesional skin of
pemphigus (Jensen, 1988; Baird, 1990). Furthermore, PA is elevated
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in the lesional skin of many other skin diseases that are not
characterized by acantholysis (Jensen, 1988; Baird, 1990; Spiers
et al, 1994, 1996). Finally, in the neonatal mouse model of
pemphigus, dexamethasone markedly suppressed (but did not
completely eliminate) PA activity induced by pemphigus IgG, but
did not affect blister formation (Anhalt et al, 1986).
Therefore, although some studies suggest that PA, particularly
uPA, may be critical to blister formation in pemphigus, other
studies do not support this hypothesis. In this study we attempt to
answer, definitively, the question of whether PA expression is
necessary for PF and PV antibodies to induce the characteristic
pathology in these diseases by using passive transfer of pemphigus
IgG to neonatal mice with targeted disruptions in the PA genes.
MATERIALS AND METHODS
PA knockout mice We purchased mice with a targeted mutation in
uPA and tPA, as reported by Carmeliet et al (1994), and bred back to a
C57Bl/6 background (Jackson Laboratories, Bar Harbor, ME). These mice
had the following genotypes: uPA–/–tPA1/1 and uPA1/1tPA–/–. In
addition to crossing mice of identical genotypes to propagate uPA–/– and
tPA–/– mice, we intercrossed uPA–/– tPA1/1 3 uPA1/1tPA–/– then
backcrossed to obtain the following breeding pairs: (i) tPA–/–uPA1/–
3 tPA1/– uPA–/–; (ii) tPA1/–uPA1/– 3 tPA–/–uPA1/–; and (iii)
tPA1/–uPA1/– 3 tPA1/–uPA–/–. These breedings supplied tPA–/– and
uPA–/– mice as well as tPA–/–uPA–/– double knockouts.
Genotyping of PA knockout mice Genomic DNA was extracted
from the tails of mice and processed for EcoRI digestion and Southern
blotting, as previously reported (Koch et al, 1997). A 1 kb Hind III–EcoRI
probe from the 39 flanking region of the tPA gene and an 0.24 kb AccI–
HindIII probe from the 39 flanking region of the uPA gene were generously
provided by Peter Carmeliet, and are referred to as tPA probe ‘‘d’’ and
uPA probe ‘‘d’’ as described (Carmeliet et al, 1994). These probes were
used as templates with random primers to synthesize 32P-labelled probes
for use on Southern blots, as previously reported (Koch et al, 1997).
Neonatal mouse model of pemphigus Neonatal mice with varying
uPA and tPA genotypes were injected with IgG purified from PV and PF
sera, as originally described by Anhalt et al (1982). Litters of 1–2 d old
neonates were injected with IgG. After µ16 h the animals were evaluated
for gross blisters, then killed for histology and to harvest DNA for
genotyping. The IgG from two PF sera and two PV sera were used; IgG
from both PF sera gave identical results as did IgG from both PV sera.
Specific procedures for preparation of IgG, injection into neonatal mice,
and evaluation of mice were essentially as recently described (Mahoney
et al, 1999). Mice were evaluated grossly, before the genotype was
determined, for spontaneous blister formation. Histology was graded
semiquantitatively, without knowing the genotype, on the following
scale: –, no blister; 11, blister at edge only; 21, localized blisters , 50%
of specimen; 31, extensive blisters . 50% of specimen; 41, very extensive
blisters . 75% of specimen.
RESULTS
Determination of pemphigus IgG dose levels to induce
extensive and more limited blisters in neonatal mice Using
normal C57Bl/6 mice as well as control littermates of uPA and
tPA knockout mice with at least one wild-type allele for both PA,
we determined approximate doses of PF and PV IgG that caused
extensive and limited blistering. These doses averaged 4.4 mg per
g (‘‘high dose’’) and 1.1 mg per g (‘‘low dose’’) for PF IgG, and
8 mg per g (‘‘high dose’’) and 3 mg per g (‘‘low dose’’) for PV
IgG. For the IgG derived from pemphigus sera in this study, as in
our previous studies, PF IgG was consistently more effective at
inducing blisters as compared with PV IgG. IgG from normal
human sera did not induce gross or microscopic blisters at any dose.
uPA is not necessary for induction of blisters by pemphigus
IgG Previous studies, discussed above, have implicated uPA as
necessary for blister formation in pemphigus. To determine if uPA
is absolutely necessary for, or modulates, blister formation in the
neonatal mouse model of pemphigus, we bred uPA–/– mice.
Southern blots of these mice and littermates with uPA probe d (see
Materials and Methods) on EcoRI restricted genomic DNA results
Figure 1. Southern blots of EcoRI restricted mouse tail DNA to
identify uPA–/–, tPA–/–, and uPA–/–tPA–/– mice. (A) uPA probe
d identifies a 5.7 kb wild-type allele (open arrowhead) and a 10 kb mutant
allele (closed arrowhead). M1 shows DNA from a uPA–/– mouse; lane C
shows DNA from a control uPA1/– mouse used to show both alleles. (B)
tPA probe d labels a 5.5 kb wild-type allele (open arrowhead) and a 9.7 kb
mutant allele (closed arrowhead) in DNA from a control tPA1/– mouse
(lane C). M2 shows DNA from a tPA–/– mouse. (C) Lanes labeled M3
show DNA from a double knockout mouse with only mutant (closed
arrowhead) uPA and tPA alleles, but no wild-type alleles (open arrowheads).
Figure 2. PA null neonatal mice injected with PF and PV IgG
develop blisters. (A) uPA–/– mouse injected with PF IgG 0.7 mg per g.
(B) uPA–/– mouse injected with PV IgG 10 mg per g. (C) uPA–/–tPA–/–
mouse injected with PF IgG 0.6 mg per g. (D) uPA–/–tPA–/– mouse
injected with PV IgG 3 mg per g. Arrow indicates flaccid blister.
in a 5.7 kb fragment from the wild-type allele and a 10 kb fragment
from the recombinant (knockout) allele in these mice (Fig 1A).
Passive transfer of PF IgG and PV IgG at both high and low doses
resulted in gross and histologic blisters in these mice, to the same
extent as uPA1/– and uPA1/1 mice (Figs 2A, B, 3A, B, and 4)
Furthermore, the histology of lesional skin was typical for PF and
PV; that is there was acantholysis in the granular layer with PF IgG
injection (Fig 3A) and there was suprabasilar acantholysis with PV
IgG injection (Fig 3B).
tPA is not necessary for blister formation in pemphigus and
does not compensate for lack of uPA Because some studies
have demonstrated increased tPA, rather than uPA, in pemphigus
lesions, we passively transferred PF and PV IgG to tPA–/– neonates.
These mice were genotyped by southern blotting with tPA probe
d which identified a 9.7 kb mutant allele and a 5.5 kb wild-type
allele (Fig 1B). tPA null mice showed blisters that were histologically
typical of PF and PV when their respective immunoglobulins were
injected (Fig 3C, D). Although there may have been a slight
tendency for less extensive blistering in tPA–/– neonates, there was
significant overlap in the extent of blistering with control mice
(Fig 4). Because the measurement of blistering was semiquantitative
at best, we did not perform a statistical evaluation, but we can
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Figure 3. Epidermal histology of PA
null mice injected with pemphigus IgG
show superficial and suprabasilar
acantholysis from PF and PV IgG,
respectively. (A) uPA–/– mouse injected
with PF IgG 0.7 mg per g. (B) uPA–/–
mouse injected with PV IgG 3 mg per g.
(C) tPA–/– mouse injected with PF IgG
1 mg per g. (D) tPA–/– mouse injected with
PV IgG 3 mg per g. (E) uPA–/– tPA–/–
mouse injected with PF IgG 0.6 mg per g.
(F) uPA–/–tPA–/– mouse injected with PV
IgG 3 mg per g.
conclude clearly that tPA is not necessary for the typical blistering
of PV or PF.
Finally, we wanted to rule out the possibility that in mice null
for one of the PA the other does not compensate, allowing blister
formation (i.e., redundancy in null animals). We therefore bred
uPA–/–tPA–/– null mice (Fig 1C). In these PA null mice, PV and
PF IgG caused blistering to the same degree as in control and
uPA–/– or tPA–/– mice (Figs 2C, D, 3E, F, and 4). The histology
of the blisters in these mice was indistinguishable from control or
single PA knockout mice (Fig 3).
DISCUSSION
These data indicate that, in the neonatal mouse model of pemphigus,
PA is not necessary for blister formation and does not, in a major
way, modulate the extent or localization of blister formation. These
studies provide further evidence that pemphigus autoantibodies
cause loss of cell adhesion directly by interference with desmoglein
function rather than indirectly by release of proteases.
These results support several lines of evidence that point to a
direct effect of pemphigus antibodies on desmoglein function. The
recently described mouse with a null mutation in Dsg3 has a
phenotype very similar to PV patients with suprabasilar blisters in
oral mucous membranes and traumatized skin (Koch et al, 1997).
This result demonstrates that the loss of function of Dsg3 results
in a similar loss of adhesion of keratinocytes as do anti-Dsg3
antibodies, suggesting that these antibodies cause loss of function.
Further evidence for a direct effect of pemphigus antibodies on
desmoglein function and against the idea of protease release as a
significant factor in blister pathogenesis comes from recent data
supporting ‘‘the desmoglein compensation hypothesis’’ as an
explanation for the localization of blisters in PF and PV (Mahoney
et al, 1999). This hypothesis states that where Dsg3 and Dsg1
expression overlap in the epidermis antibodies against either one
will not cause spontaneous blisters, but antibodies against both will
do so. On the other hand where Dsg3 or Dsg1 is expressed alone,
antibodies against that desmoglein will cause a blister. These data
Figure 4. Similar extent of histologic blistering in control and PA
mutant mice. High dose: mean for PF IgG 4 mg per g; for PV 8 mg per
g. Low dose: mean for PF IgG 1 mg per g; for PV 3 mg per g. 1, At least
one wild-type allele each for uPA and tPA. u-, uPA–/– with at least one
wild-type allele for tPA. t-, tPA–/– with at least one wild-type allele for
uPA. –/–, no PA wild-type alleles. Extent of blistering graded by a
semiquantitative scale as described in Materials and Methods.
are consistent with the idea that antibodies in pemphigus interfere
with desmoglein function, and are not consistent with the idea
that antibodies that bind to a desmoglein release a protease which
causes the blister (because in the later case the second desmoglein
would not be expected to compensate).
Although formally we have not ruled out that PA play a major
part in human, as opposed to mouse, pemphigus, we think it highly
unlikely that pemphigus autoantibodies would cause identical
histologic lesions in mice and humans, but by different mechanisms.
Although it is possible that PA and perhaps other proteases modulate
the extent of blister formation in pemphigus patients, the weight
of the current evidence suggests that the major pathophysiologic
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mechanism in pemphigus is a direct effect of autoantibodies on the
function of desmogleins and the desmosomes in which they
are found.
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